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Abstract
Background: Genetic polymorphism is an inevitable component of a multistage infectious organism, such as the
malaria parasite. By means of genetic polymorphism, parasite opts particular polymorph and reveals survival
advantage. Pvs25 and pvs28 are sexual stage antigen genes, expressed at the ookinete stage inside the mosquito
gut, and considered as potential transmission-blocking vaccine candidates. This study presents sequence variations
in two important transmission blocking antigen genes pvs25 and pvs28 in the field isolates of P. vivax from the
Indian subcontinent.
Methods: One hundred microscopically diagnosed P. vivax isolates were collected from five geographical regions
of India. Pvs25 and pvs28 genes were PCR amplified and sequenced to assess sequence variation among field
isolates.
Results: A total of 26 amino acid substitutions were observed in Pvs25 (10) and Pvs28 (16) among field isolates of
P. vivax. Tandem repeat polymorphism observed in pvs28 shows 3-6 tandem repeats in the field isolates. Seven and
eight novel amino acid substitutions were observed in Pvs25 and Pvs28, respectively in Indian isolates. Comparison
of amino acid substitutions suggests that majority of substitutions observed in global isolates were also present in
Indian subcontinent. A single haplotype was observed to be major haplotype among isolates of Delhi, Nadiad,
Chennai and Panna except in isolates of Kamrup. Further, population comparison analyses suggest that P. vivax
isolates inhabiting in north-eastern region (Kamrup) were distantly related with the isolates from remaining parts of
the country. Majority of the amino acid substitutions observed in Indian isolates were more identical to the
substitutions reported from isolates of Thailand and Bangladesh.
Conclusion: Study uncovered many new amino acid substitutions as well as a predominance of single haplotype
in Indian subcontinent except in north-eastern region of the country. The amino acid substitutions data generated
in this study from different geographical regions of the Indian subcontinent could be helpful in designing a more
effective anti-malarial transmission-blocking vaccine.
Background
Malaria is a life-threatening ancient parasitic disease and
causes 250-500 million clinical episodes and nearly one
million deaths annually [1]. Among the five human
malaria species, Plasmodium falciparum is the most
severe form, causing malignant malaria globally, while
Plasmodium vivax is the most widespread species out-
side Africa, causing huge morbidity, and rarely severe
and fatal [2-7]. In general, the biology of P. vivax differ
with P. falciparum in three major way 1) relapse, 2)
mild disease, and 3) preference of reticulocytes for
invasion.
The ookinete surface proteins of Plasmodium are the
targets for a transmission-blocking vaccine [8-11]. Pfs25,
pfs28 and their orthologs in Plasmodium species infect-
ing to human, primate and rodent share a common con-
served structure consisting of four tandem epidermal
growth factor like domains (EGF) anchored with para-
site surface by a glycosylphosphatidylinositol moiety.
The purified proteins Pvs25 and Pvs28 along with
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response in mice. The immune response against sexual
stage antigens impaired development of sexual stage of
malaria parasite inside mosquito that supports sexual
stage antigens can be a potential transmission-blocking
v a c c i n e[ 1 2 ] .H o w e v e r ,g e n e t i cp o l y m o r p h i s mi nt h e s e
vaccine candidates can hamper the efficacy of vaccine.
Therefore, identifying genetic variations in sexual stage
antigen genes is an important task before designing
effective anti-malarial control measures.
I n d i ai sav a s tc o u n t r yc o n t r i b u t i n gu pt o7 7 . 0 %o f
total malaria cases reported in Southeast Asia [13]. Plas-
modium vivax infections account for more than 50% of
the total malaria cases in India and it is one of the two
most prevalent malaria parasite species in India. Genetic
polymorphism in transmission-blocking vaccine candi-
dates has been reported from various malaria endemic
countries such as South and Central America [14-17],
Iran [18], Korea [19], Bangladesh [15] and Southeast
Asia [15,20] except from the Indian subcontinent. How-
ever, in order to uncover the population specific novel
polymorphisms and common variations, identification of
genetic variations using population level approach is
essential. This study presents antigenic repertoires of
sexual stage antigens (Pvs25 and Pvs28) of P. vivax iso-
lates from different geographical regions of Indian
subcontinent.
Methods
Study sites and sample collection
Blood samples were collected from five widely separated
geographical regions of the Indian subcontinent namely
Delhi (2005); Chennai, Tamil Nadu (2005); Kamrup,
Assam (2007); Nadiad, Gujarat (2005) and Panna, Mad-
hya Pradesh (2006). Details of epidemiological and geo-
graphical information about these study sites are
reported elsewhere [21]. Finger prick blood was spotted
on autoclaved Whatman filter paper strips (Number 3)
from the symptomatic patients in active case detection
surveys as well as from patient attending clinics. A total
of one hundred microscopically diagnosed P. vivax posi-
tive (20 from each site) bloods were spotted on auto-
claved Whatman filter paper strips (Number 3) and
were stored at 4.0°C. This study was approved by the
ethics committee of the National Institute of Malaria
Research, New Delhi. All bloodspots were collected only
after obtaining consent of the patients.
DNA extraction, PCR, and DNA sequencing
Genomic DNA was extracted from bloodspots using
QIAamp mini DNA kit as per manufacturer’si n s t r u c -
tions. Genomic DNA was eluted in 120.0 μl triple sterile
water and store in -20°C until use. One step modified
PCR strategy was employed for amplification of pvs25/
pvs28 reported earlier [20]. PCR products were cleaned
up using Exonuclease I/Shrip alkaline phosphates treat-
ment according to manufacturer’s instructions. Purified
PCR products were outsourced to Macrogen Inc, Korea
for DNA sequencing [22]. Each sample was sequenced
with both forward and reverse primers. DNA sequences
were edited and aligned (ClustalW method) with Edit-
S e qa n dM e g A l i g nm o d u l eo fD N AL a s e r g e n es o f t w a r e
version 7.0 (Madison, USA). All sequences have been
submitted to the GenBank (HM048519-HM048618,
FJ490913-FJ490962 and JF824132-JF824147). All
sequences of pvs25 and pvs28 were compared with Sal-1
reference sequences of accession no. AF083502 and
AF083503, respectively for mutation identification.
Population genetic structure
Population structure of P. vivax among five different
geographical regions was estimated with pair-wise FST
difference in population comparison test, using Arlequin
software package [23]. This method provides statistical
power to view genetic distance among different popula-
tions/geographical regions on the basis of frequency dis-
tribution of haplotypes.
Results
Pvs25 gene was successfully PCR amplified and
sequenced from 100 P. vivax isolates collected from five
geographical regions (N = 20 from each study site). PCR
amplified fragment was 830 bp in length, which covers
an upstream non-coding (1-223 bp) and a coding (224-
830 bp) region. DNA sequence analysis revealed a total
of 16 nucleotide substitutions in both non-coding (4)
and coding (12) fragments and an insert of seven
nucleotides (TACTTGC) in non-coding fragment.
Within the coding region, two nucleotide substitutions
were synonymous whereas ten were non-synonymous.
All non-synonymous substitutions are listed in Table 1.
The domain-wise analysis revealed a single amino acid
substitution in EGF-2 (E97K), four in EGF-3 (I130T,
Q131K, C137W, and A138G), and five in EGF-4
(E174K, E183K, S196F, S198T and V199E) (Table 1).
Among these amino acid substitutions, E97K (EGF-2)
and I130T, Q131K (EGF-3) were observed to be poly-
morphic whereas remaining seven were singletons
(mutations observed only in single sequence out of total
sequences analysed).
Pvs28 was successfully PCR amplified and sequenced
from 66 isolates collected from five geographical regions
namely Delhi (N = 15), Panna (N = 6), Nadiad (N = 11),
Chennai (N = 14), and Kamrup (N = 20). PCR amplified
fragment was 650 bp in length and covers coding domains
of signal sequence, EGF-1 to EGF-4, and C terminal
hydrophobic region (THR). A total of 18 segregating sites
and 21 nucleotide substitutions were observed in the study
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were synonymous whereas 16 were non-synonymous. The
majority of substitutions were singletons in nature (11/21).
All non-synonymous substitutions are listed in Table 2.
The observed domain wise analysis revealed two amino
acid substitutions in a signal sequence (H5T and H5Y),
two in EGF-1 (M52L and A53V), four in EGF-2 (T65K,
V79E, L98I and E105K), two in EGF-3 (L116V and
T140S), two in EGF-4 (G191D and D210G), and four in
THR (G212R, S216T, V223L and I224M). Out of 16, eight
amino acid substitutions are observed to be novel. The
novel amino acid substitutions were mapped in the
domains of signal sequence (H5T and H5Y), EGF-2
(V79E), EGF-4 (G191D and D210G), and THR (G212R,
S216T and V223L).
Geographical distribution and comparison with global
amino acid substitutions
In Pvs25, E97K and I130T were the most common
amino acid substitutions observed in isolates of five
Table 1 Pvs25 amino acid substitutions in Indian and global isolates of Plasmodium vivax
Geographical regions SS EGF-1 EGF-2 EGF-3 EGF-4 References
0
0
2
0
8
7
0
9
7
1
3
0
1
3
1
1
3
2
1
3
7
1
3
8
1
4
9
1
7
0
1
7
4
1
8
3
1
9
6
1
9
8
1
9
9
Sal-1 strain N Q E I Q S C A K C E E S S V [14]
Iran - Q/K E/Q T - - - - - - - - - - - [18]
Turkey N/D K - T - - - - - - - - - - - #
India - - Q T - - - - - - - - - - - [16]
Bangladesh - - E/Q T K - - - - - - - - - - [15]
Thailand - - E/Q T Q/K - - - - - - - - - - [20]
Indonesia - - Q T Q - - - - - - - - - - [16]
Viet Nam N/D - - T - - - - - - - - - - - #
N Korea - - - T - - - - - - - - - - - [16]
S Korea N/D - E/Q T - - - - - - - - - - - [19]
PNG - - - T K R - - N - - - - - - [15]
Mexico - Q/K - T - - - - - - - - - - - [17]
Honduras - - - - - - - - - - - - - - - [16]
El Salvador - - - - - - - - - - - - - - - [16]
Colombia - K - - - - - - - - - - - - - [16]
Brazil - Q/K - - - - - - - - - - - - - [16]
Nicaragua - - - - - - - - - R - - - - - [16]
India - - E/Q T Q/K - C/W A/G - - E/K E/K S/F S/T V/E *
Bold face values: amino acid substitution position, #: Unpublished data, *: Data of present study
Table 2 Pvs28 amino acid substitutions in Indian and global isolates of Plasmodium vivax
Geographic
regions
SS EFG-1 EGF-2 EGF-3 EGF-4 THR References
0
0
5
0
5
2
0
5
3
0
6
5
0
7
9
0
8
1
0
9
5
0
9
8
105 1
0
6
110 113 1
1
6
1
4
0
1
5
9
191 Repeats 2
1
0
212 216 2
2
3
224
Sal-1 strain H M A T V A G L E V Y N L T K G 6 D G S V I [14]
Iran - L - T/
K
- - - - - - - - - S - - 4-6 - - - - - [18]
India - L - K - - - - - - - - - S - - 4 - - - - - [15]
Bangladesh - M/
L
-T /
K
--- L /
I
-N S L /
V
T/
S
K/
R
- 5-7 - - - - I/M [15]
Thailand - M/
L
A/
V
T/
K
-A /
V
G/
N
L/
I
E/K V/
E
N- L /
V
T/
S
- - 5-7 - - - - - [20]
Mexico - L - T - - - - - - - - - S - - 5-6 - - - - - [17]
S Korea - L - - - - - - - - - - - S - - 6 - - - - - [19]
India H/T/
Y
M/
L
A/
V
T/
K
V/
E
-- L /
I
E/K - - - L/
V
T/
S
- D 3-6 D/
G
G/R S/T V/
L
I/M *
Bold face values: amino acid substitution position, and *: Data of present study
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amino acid substitution Q131K was very frequent in iso-
lates of Kamrup region (55.0%), very less in isolate from
Panna (5.0%) and Chennai (5.0%), and was absent in iso-
lates of Nadiad and Delhi. Region specific amino acid
substitutions were observed more in isolates from
Kamrup (C137W, A138G, E174K and S196F) and less in
isolates from Delhi (E183K), Panna (S198T) and Nadiad
(V199E). None of the amino acid substitution was
observed to be specific for isolates of Chennai. Compari-
son of amino acid substitutions observed in present
study with those reported in global isolates suggest that
amino acid substitutions in EGF-1 (E97K) and EGF-2
(E97K and Q131K) were present in global as well as in
Indian isolates. However, amino acid substitutions found
in signal sequence and EGF-1 domains were not
observed in Indian isolates. EGF-3 revealed amino acid
substitution at codon 132, found only in isolates of
Papua New Guinea, was not observed in Indian isolates
(Table 1).
In Pvs28, M52L, T65K and T140S were the most
common amino acid substitutions observed among five
geographical regions of the Indian subcontinent. The
seven amino acid substitutions (A53V, V79E, L98I,
E105K, L116V, V223L and I224M) were observed to be
specific for isolates of Kamrup region, whereas four
were specific for Chennai (G191D, D210G, G212R and
S216T) and one was for Panna (H5T) and Nadiad
(H5Y). None of the region specific amino acid substitu-
tions were observed in isolates of Delhi. The eight
amino acid substitutions observed in present study
(Table 2) were also reported from the global isolates.
Majority of amino acid substitutions observed in isolates
of Kamrup region were more identical to the amino
acid substitutions found in isolates of Bangladesh and
Thailand. On the basis of amino acid substitution, iso-
lates from Nadiad, Panna, Chennai and Delhi did show
more similarity compared to the isolates from the
north-eastern region (Kamrup) of the country. Several
of the amino acid substitutions (Codon 81, 95, 106, 110,
113 and 159) found in global isolates were not observed
in the Indian subcontinent.
Tandem repeat polymorphism
Tandem repeat polymorphism at Pvs28 was observed
due to deletion/insertion of five amino acid repeat unit
(GEGGS/D) in study isolates from all geographical
regions of Indian subcontinent. Four tandem repeat var-
iants observed in present study, were (GEGGS/D)3,
(GEGGS/D)4, (GEGGS/D)5, and (GEGGS/D)6. Tandem
repeat variants (GEGGS/D)4 and (GEGGS/D)5 were
observed in all five geographical regions whereas tandem
repeat (GEGGS/D)3 and (GEGGS/D)6 were only
observed in isolates of Delhi and Kamrup regions,
respectively (Table 3). Tandem repeat variant (GEGGS/
D)6 observed in isolates of Kamrup region, was also
commonly found in isolates from adjoining countries,
such as Bangladesh and Thailand. Among global iso-
lates, 4-7 tandem repeats of GEGGS/D were found,
whereas in Indian isolates, an additional variant of
(GEGGS/D)3, was observed.
Population genetic structure
Haplotyping using DNA sequence polymorphism
revealed 10 and 15 haplotypes in pvs25 and pvs28,
respectively. Haplotype frequency distribution revealed a
single major haplotype at pvs25 (Hap1) and pvs28
(Hap8) among five geographical regions of the Indian
subcontinent (Table 4). Highest number of haplotypes
was observed in isolates of Kamrup (north-eastern
region). All though, few haplotypes observed in relatively
low frequency at pvs25 (9) and pvs28 (14) were specific
to a particular population. Pair-wise comparison using
Fst difference between populations is presented in Fig-
ure 1. The pair-wise Fst difference on the basis of both
pvs25 and pvs28 haplotypes, revealed that all studied
populations significantly differ with Kamrup population
(north-eastern region) with a non-significant differentia-
tion among the four regions (Panna, Delhi, Nadiad, and
Chennai) (Figure 1). The FST values showed existence of
significant level of gene flow among isolates of Chennai,
Delhi, Panna, and Nadiad regions.
Discussion
The worldwide spread of drug resistant Plasmodium
species compounding the lack of anti-malarial vaccine in
near future calls for identifying the new vaccine/drug
targets in order to design more effective anti-malarial
control measures. The excellent capability of parasite for
generating polymorphism for its survival is the major
challenging task for designing anti-malarial vaccine.
Pvs25 and Pvs28 are the two promising candidates for
the development of anti-malarial transmission blocking
vaccine [12]. The antigenic diversity reported in target
molecules (Pvs25 and Pvs28) could hinder the efficacy
of vaccine [14,18,20]. Therefore, identifying sequence
variations in transmission-blocking vaccine candidates
Table 3 Tandem repeat polymorphism at Pvs28 and their
distribution in different geographical regions of India
Tandem repeats Distribution of tandem repeat variants (%)
Delhi Chennai Panna Nadiad Kamrup
(GEGGS/D)3 13.33 0 0 0 0
(GEGGS/D)4 73.34 50.0 83.33 55.46 5.0
(GEGGS/D)5 13.33 50.0 16.67 54.54 10.0
(GEGGS/D)6 0 0 0 0 85.0
Total (N) 15 14 6 11 20
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vaccine.
A previous study has identified limited polymorphism in
both Pvs25 and Pvs28 in P. vivax clinical isolate collected
from a Japanese tourist, who had acquired infection from
India. In contrast, present prospective study identified
many additional amino acid substitutions in Indian sub-
continent at both Pvs25 and Pvs28 (Table 1 and 2). Indian
isolates revealed 10 and 15 amino acid substitutions at
Pvs25 and Pvs28, respectively, which is more than to that
observed among global isolates. This suggests that muta-
tions in both sexual stage antigen genes are not limited, as
previously it was reported. More than 50% of the major
amino acid substitutions observed at Pvs25 and Pvs28 in
global isolates were shared by Indian isolates which sug-
gests that Indian isolates harbours major pool of global
sexual stage antigenic repertoires.
Comparison of amino acid substitutions at both Pvs25
and Pvs28 suggests that majority of the substitutions
observed in Indian isolates were similar to the amino
acid substitutions reported in isolates from Thailand
and Bangladesh. All though, sequence polymorphism at
Pvs25 & Pvs28 was investigated using limited number of
isolates from Bangladesh [15], and Southeast Asia
[15,16,20]. The present data suggests that by increasing
sample size from these countries, it could be possible to
uncover much additional amino acid substitution. The
higher number of amino acid substitutions observed in
present study compared with global isolates could be
due to large samples analyzed, which were collected
from five widely separated geographical regions of India.
Regardless of many haplotypes observed in present
study, the major haplotype appeared to be single at both
Pvs25 & Pvs28 (Table 4) in four geographic regions
(Delhi, Panna, Nadiad and Chennai). Similarly, the Fst
analysis suggests that genetic structure of parasite pre-
sent in north-eastern region is different than remaining
part of the Indian subcontinent. The amino acid substi-
tutions and tandem repeat polymorphism data collec-
tively suggests that isolates from north-eastern region
have more similarity with the isolates from Bangladesh
and Thailand. This is strongly supported with a recent
study that suggests a higher frequency of quadruple
mutant pvdhfr genotype (61.9%) in north-eastern region
[24]. The frequency of quadruple mutant pvdhfr geno-
type is rarely observed in remaining part of the country,
however it is a major genotype in isolates of Myanmar
(71.0%) and Thailand (96.0%) [25,26]. The higher
genetic identity of P. vivax isolates from north-eastern
region with the isolates from Bangladesh and Thailand
could be due to 1) similarity in malaria transmitting vec-
tor species (Anopheles minimus and Anopheles dirus)
[27] due to similar geographical environment, and 2) as
north-eastern states are surrounded by international
borders and frequent migration of peoples is possible
due to porous borders. These above factors may contri-
bute the inflow of malaria parasites in adjoining north-
eastern region of the country.
This study added seven and eight novel amino acid sub-
stitutions in Pvs25 and Pvs28 respectively suggesting the
importance of population level approach to identify amino
acid substitutions in vaccine candidates. The total number
of global substitutions increases from 8 to 15 at Pvs25 and
14 to 21 at Pvs28. The increase in number of amino acid
substitutions at the two sexual stage antigens may ham-
pers effectiveness of Sal 1 strain based transmission-block-
ing vaccine [12] in different geographical regions of the
globe. Though, one study has evaluated similar efficacy of
Sal-1 strain based vaccine for variants sequence observed
in Thai isolates that suggest that Sal-1 strain based vaccine
could have wider usability [20]. Since, most of the amino
acid substitutions observed in Indian isolates were similar
to those observed in isolates of Thailand, therefore, one
could expect that Sal-1 strain based transmission-blocking
vaccine could work in Indian geographic regions.
Table 4 Frequency distribution of haplotypes at pvs25
and pvs28 among Indian subcontinent
Pvs25 Geographic location
Haplotype Delhi
(N = 20)
Nadiad
(N = 20)
Panna
(N = 20)
Chennai
(N = 20)
Kamrup
(N = 20)
Hap1 0.95 0.85 0.90 0.95 0.30
Hap2 0 0 0 0.05 0.35
Hap3 0.05 0 0 0 0
Hap4 0 0.10 0 0 0
Hap5 0 0.05 0 0 0
Hap6 0 0 0.05 0 0.15
Hap7 0 0 0 0 0.05
Hap8 0 0 0 0 0.05
Hap9 0 0 0 0 0.10
Hap10 0 0 0.05 0 0
Pvs28 (N = 15) (N = 11) (N = 6) (N = 14) (N = 20)
Hap1 0 0 0 0 0.05
Hap2 0 0 0 0 0.05
Hap3 0 0 0 0 0.05
Hap4 0 0 0 0 0.05
Hap5 0 0 0 0 0.05
Hap6 0 0 0 0 0.10
Hap7 0 0 0 0 0.10
Hap8 1 0.91 0.83 0.85 0.25
Hap9 0 0 0 0 0.10
Hap10 0 0 0 0 0.05
Hap11 0 0 0 0 0.15
Hap12 0 0 0.16 0 0
Hap13 0 0 0 0.07 0
Hap14 0 0 0 0.07 0
Hap15 0 0.09 0 0 0
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vaccine, evaluation of the Sal-1 strain based vaccine for all
major haplotypes observed in Indian and global isolates
may be warranted.
In conclusion, present study uncovered several new
amino acid substitutions at both Pvs25 and Pvs28
among Indian isolates and the most frequent amino acid
substitutions observed, were shared by global isolates. P.
vivax isolates from north-eastern region are different
from remaining part of Indian subcontinent and have
high similarity with the isolates from Bangladesh and
Thailand. The amino acid substitution data of present
study would be helpful in designing a more appropriate
effective anti-malarial transmission-blocking vaccine.
Acknowledgements
This work is supported by Department of Biotechnology, New Delhi. SKP is
an ICMR Postdoctoral Fellow. The authors are thankful to the patients for
0.409, 0.303 
0.440, 0.457 
0.395, 0.393 
0.330, 0.411 
0
.
0
2
3
,
 
0
.
0
0
9
 
0
.
1
6
6
,
 
0
.
0
 
0.012, 0.015 
-
0
.
0
0
7
,
 
0
.
0
2
4
 
0.029, 0.015 
0
.
0
0
5
,
 
0
.
0
2
2
 
Kamrup 
Delhi 
Nadiad 
Panna 
Chennai 
Figure 1 Genetic differentiation between geographical regions of Indian subcontinent. Red line colour indicates Fst with significant p
value (p < 0.001) between populations. Black line indicates Fst with non-significant p value (p > 0.05) between populations. Values in black and
blue colours represent Fst estimated at pvs25 and pvs28 respectively.
Prajapati et al. Malaria Journal 2011, 10:111
http://www.malariajournal.com/content/10/1/111
Page 6 of 7their co-operation during the study. The authors are also thankful to
scientist/staff of National Institute of Malaria Research, New Delhi as well as
from field station for their support and help during the study. Authors
express their deep gratitude to Dr. Hema Joshi, who passed away recently
and she had contributed significantly to the present study.
Authors’ contributions
SKP carried out the experiment design, experimental work, data analysis, and
manuscript writing, HJ conceived and coordinated the study, and VKD
supervised overall work and contributed in data analysis and manuscript
writing. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 January 2011 Accepted: 2 May 2011 Published: 2 May 2011
References
1. WHO: Annual Report. World Health Organization, Geneva 2008.
2. Andrade BB, Reis-Filho A, Souza-Neto SM, Clarencio J, Camargo LM, Barral A,
Barral-Netto M: Severe Plasmodium vivax malaria exhibits marked
inflammatory imbalance. Malar J 2010, 9:13.
3. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A,
Khatri MP, Gupta V: Severe Plasmodium vivax malaria: a report on serial
cases from Bikaner in northwestern India. Am J Trop Med Hyg 2009,
80:194-198.
4. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A: Plasmodium
vivax malaria. Emerg Infect Dis 2005, 11:132-134.
5. Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I:
Plasmodium vivax and mixed infections are associated with severe
malaria in children: a prospective cohort study from Papua New Guinea.
PLoS Med 2008, 5:e127.
6. Rogerson SJ, Carter R: Severe vivax malaria: newly recognised or
rediscovered. PLoS Med 2008, 5:e136.
7. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M,
Lampah DA, Price RN: Multidrug-resistant Plasmodium vivax associated
with severe and fatal malaria: a prospective study in Papua, Indonesia.
PLoS Med 2008, 5:e128.
8. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC:
Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria
transmission-blocking immunity in experimental animals. J Exp Med 1991,
174:1203-1208.
9. Kaslow DC, Shiloach J: Production, purification and immunogenicity of a
malaria transmission-blocking vaccine candidate: TBV25H expressed in
yeast and purified using nickel-NTA agarose. Biotechnology (NY) 1994,
12:494-499.
10. Duffy PE, Kaslow DC: A novel malaria protein, Pfs28, and Pfs25 are
genetically linked and synergistic as falciparum malaria transmission-
blocking vaccines. Infect Immun 1997, 65:1109-1113.
11. Gozar MM, Price VL, Kaslow DC: Saccharomyces cerevisiae-secreted fusion
proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum
transmission-blocking antibodies in mice. Infect Immun 1998, 66:59-64.
12. Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS,
Suwanabun N, Torii M, Kaslow DC: Antibodies to malaria vaccine
candidates Pvs25 and Pvs28 completely block the ability of Plasmodium
vivax to infect mosquitoes. Infect Immun 2000, 68:6618-6623.
13. Kumar A, Valecha N, Jain T, Dash AP: Burden of malaria in India:
retrospective and prospective view. Am J Trop Med Hyg 2007, 77:69-78.
14. Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM, Torii M: Sequence
polymorphism in two novel Plasmodium vivax ookinete surface proteins,
Pvs25 and Pvs28, that are malaria transmission-blocking vaccine
candidates. Mol Med 1998, 4:772-782.
15. Tsuboi T, Kaneko O, Cao YM, Tachibana M, Yoshihiro Y, Nagao T, Kanbara H,
Torii M: A rapid genotyping method for the vivax malaria transmission-
blocking vaccine candidates, Pvs25 and Pvs28. Parasitol Int 2004,
53:211-216.
16. Escalante AA, Cornejo OE, Freeland DE, Poe AC, Durrego E, Collins WE,
Lal AA: A monkey’s tale: the origin of Plasmodium vivax as a human
malaria parasite. Proc Natl Acad Sci USA 2005, 102:1980-1985.
17. Gonzalez-Ceron L, Alvarado-Delgado A, Martinez-Barnetche J,
Rodriguez MH, Ovilla-Munoz M, Perez F, Hernandez-Avila JE, Sandoval MA,
Rodriguez Mdel C, Villarreal-Trevino C: Sequence variation of ookinete
surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from
Southern Mexico and their association to local anophelines infectivity.
Infect Genet Evol 2010, 10:645-654.
18. Zakeri S, Razavi S, Djadid ND: Genetic diversity of transmission blocking
vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax
clinical isolates from Iran. Acta Trop 2009, 109:176-180.
19. Han ET, Lee WJ, Sattabongkot J, Jang JW, Nam MH, An SS, Suh I, Lim CS:
Sequence polymorphisms of Plasmodium vivax ookinete surface proteins
(Pvs25 and Pvs28) from clinical isolates in Korea. Trop Med Int Health
2010.
20. Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N,
Rungruang T, Cao YM, Stowers AW, Sirichaisinthop J, Coleman RE, Torii M:
Blocking of transmission to mosquitoes by antibody to Plasmodium
vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic
polymorphism in field isolates. Am J Trop Med Hyg 2003, 69:536-541.
21. Prajapati SK, Verma A, Adak T, Yadav RS, Kumar A, Eapen A, Das MK,
Singh N, Sharma SK, Rizvi MA, Dash AP, Joshi H: Allelic dimorphism of
Plasmodium vivax gam-1 in the Indian subcontinent. Malar J 2006, 5:90.
22. Macrogen Inc. Korea. [http://www.macrogen.com].
23. Excoffier L, Laval G, Schneider S: Arlequin (version 3.0): an integrated
software package for population genetics data analysis. Evol Bioinform
Online 2005, 1:47-50.
24. Prajapati SK, Joshi H, Dev V, Dua VK: Molecular epidemiology of
Plasmodium vivax anti-folate resistance in India. Malar J 2011, 10:102.
25. Na BK, Lee HW, Moon SU, In TS, Lin K, Maung M, Chung GT, Lee JK, Kim TS,
Kong Y: Genetic variations of the dihydrofolate reductase gene of
Plasmodium vivax in Mandalay Division, Myanmar. Parasitol Res 2005,
96:321-325.
26. Lu F, Lim CS, Nam DH, Kim K, Lin K, Kim TS, Lee HW, Chen JH, Wang Y,
Sattabongkot J, Han ET: Mutations in the antifolate-resistance-associated
genes dihydrofolate reductase and dihydropteroate synthase in
Plasmodium vivax isolates from malaria-endemic countries. Am J Trop
Med Hyg 2010, 83:474-479.
27. Manguin S, Garros C, Dusfour I, Harbach RE, Coosemans M: Bionomics,
taxonomy, and distribution of the major malaria vector taxa of
Anopheles subgenus Cellia in Southeast Asia: an updated review. Infect
Genet Evol 2008, 8:489-503.
doi:10.1186/1475-2875-10-111
Cite this article as: Prajapati et al.: Antigenic repertoire of Plasmodium
vivax transmission-blocking vaccine candidates from the Indian
subcontinent. Malaria Journal 2011 10:111.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Prajapati et al. Malaria Journal 2011, 10:111
http://www.malariajournal.com/content/10/1/111
Page 7 of 7